News
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that its Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (USFDA).
JEOL: Release of Scanning Electron Microscopes JSM-IT710HR/JSM-IT210
JEOL Ltd. (TOKYO:6951) (President & CEO Izumi Oi) announces the release of scanning electron microscopes JSM-IT710HR/JSM-IT210 on July 23, 2023.
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced a clinical supply agreement with AstraZeneca in China.
Astellas Completes Acquisition of Iveric Bio
stellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio") with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition").
Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in Molecular Metabolism.
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) in combination with obinutuzumabfor the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after at least two prior lines of therapy.
Eisai to Present the Latest Alzheimer’s Disease Pipeline and Research, including Lecanemab and Anti-MTBR TAU Antibody E2814, at the Alzheimer’s Association International Conference 2023
Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI®), and the company's investigational anti-MTBR** tau antibody, E2814, at the Alzheimer's Association International Conference (AAIC).
Samsung Bioepis Releases its Second US Biosimilar Market Report
Samsung Bioepis Co., Ltd. today released the second edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States.
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced it presented four posters at the 25th World Congress of Dermatology being held in Singapore from July 3-8, 2023.
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
Sirnaomics Ltd. (the "Company", stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby announces that Sirnaomics' Senior Director of Technology Innovation, Dr. Weterings will present the latest developments on its of GalAhead™, GalNAc-RNAi therapeutic platforms and related pipeline programs at international industry conferences taking place in July.
